INVIVO PHARMACOKINETICS OF THE ANTITUMOR AGENT 4,6-BENZYLIDENE-D-GLUCOSE (BG) AND A DEUTERATED ANALOG 4,6-BENZYLIDENE-D1-D-GLUCOSE (P-1013) IN MICE, RATS AND DOGS
- Authors:
- Published online on: January 1, 1993 https://doi.org/10.3892/ijo.2.1.61
- Pages: 61-66
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
In vivo pharmacokinetics of the antitumour agent 4,6-benzylidene-D-glucose (BG) and a deuterated analog 4,6-benzylidene-d1-D-glucose (P-1013) were investigated in athymic mice, Beagle dogs and Wistar rats following i.v. administration of the compounds. Reverse-phase high performance liquid chromatography (HPLC) was used to quantitate drug and metabolite content in plasma samples. No difference in the half-life (t1/2) for BG and P-1013 was observed in any of the three species, the half-lives were on the order of 10 min. Metabolism of BG and P-1013 leads to formation of undeuterated and deuterated 1,3-benzylidene-D-glucitol, respectively, as the only detectable metabolites. The half-lives of these metabolites were also measured and were found to differ between rats given undeuterated and deuterated drug. In mice and dogs the t1/2 was the same for deuterated and undeuterated 1,3-benzylidene-D-glucitol.